Medical Cannabis Research Australia


Attention Deficit Hyperactivity Disorder

Medical Cannabis for Adult ADHD:

Sociological Patient Case Report of Cannabinoid Therapeutics in Finland; Status of Medical Cannabis Patients

The current study provides the first detailed investigation of CT for a male combined-type adult ADHD patient in Finland who accessed Bedrocan® and Bediol® for more than 5 years. The patient found relief for his ADHD symptoms, the cannabinoids offering reduced hyperactivity as well as improved focus, impulse control, and better frustration tolerance. This is in line with clinical studies on medical cannabis for ADHD. In addition, the patient experienced other medical benefits that contributed to his overall wellbeing, especially with the combination of the high-dronabinol product Bedrocan® and the moderate-dronabinol/high-CBD product Bediol® [31].
Medical Cannabis and Cannabinoids, 2018;1:112–118

Cannabinoid and Terpenoid Doses are Associated with Adult ADHD

Status of Medical Cannabis Patients

These results, although not causal, might shed light on the potential beneficial effects of MC on ADHD symptom severity and motivate future prospective studies in order to validate our results and perhaps even consider making ADHD an approved indication for MC license in Israel in future.
Rambam Maimonides Medical Journal, January, 2020

Cannabinoids in Attention-Deficit/Hyperactivity Disorder:

A Randomised-Controlled Trial

Adults with ADHD may represent a subgroup of individuals who experience a reduction of symptoms and no cognitive impairments following cannabinoid use. While not definitive, this study provides preliminary evidence supporting the self-medication theory of cannabis use in ADHD and the need for further studies of the endocannabinoid system in ADHD.

Rambam Maimonides Medical Journal, January, 2020